Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Esophageal NeoplasmsStomach NeoplasmsNeoplasm Metastasis
Interventions
DRUG

Regorafenib

The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle

DRUG

Paclitaxel

Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.

Trial Locations (1)

1100 DD

Academic Medical Center, Medical Oncology, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT02406170 - Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma | Biotech Hunter | Biotech Hunter